Literature DB >> 18690339

Characterization of a novel mutation in the von Willebrand factor propeptide in a distinct subtype of recessive von Willebrand disease.

Elsa Lanke1, Ann-Charlotte Kristoffersson, Malou Philips, Lars Holmberg, Stefan Lethagen.   

Abstract

von Willebrand factor (VWF) is a plasma protein that consists of a series of multimers of which the high-molecular-weight VWF multimers are the most potent in platelet adhesion and aggregation. The propeptide of the VWF (VWFpp) is known to be essential in the process of multimer assembly. Genetic studies were performed in a patient with a phenotype of von Willebrand disease (VWD) characterized by very low plasma factor VIII and VWF levels and a VWF consisting of only a dimeric band and total absence of all multimers in plasma. The patient was found to be homozygous for the novel C570S mutation, caused by a 1709G>C transition in exon 14 of the VWF gene coding for the propeptide. Three asymptomatic relatives were found to be heterozygous. In-vitro mutagenesis and expression in COS-7 cells confirmed the detrimental effect of the mutation on VWF multimerization. Our findings show that the C570S mutation in the VWFpp abolishes multimerization of VWF. The mutation probably disrupts the normal configuration of the VWFpp, which is essential for correct orientation of the protomers and ultimately multimerization. The mutant amino acid is located in a region that is highly conserved across several species which underlines its critical role. This variant constitutes a distinct subtype of recessive 2A VWD with the exclusive presence of the dimeric form of VWF in plasma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690339

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Authors:  T Obser; M Ledford-Kraemer; F Oyen; M A Brehm; C V Denis; R Marschalek; R R Montgomery; J E Sadler; S Schneppenheim; U Budde; R Schneppenheim
Journal:  J Thromb Haemost       Date:  2016-08-20       Impact factor: 5.824

2.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

3.  Phenotypic expression of ADAMTS13 in glomerular endothelial cells.

Authors:  Ramesh Tati; Ann-Charlotte Kristoffersson; Anne-Lie Ståhl; Matthias Mörgelin; David Motto; Simon Satchell; Peter Mathieson; Minola Manea-Hedström; Diana Karpman
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

4.  Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.

Authors:  Ramesh Tati; Ann-Charlotte Kristoffersson; Minola Manea Hedström; Matthias Mörgelin; Jörgen Wieslander; Cees van Kooten; Diana Karpman
Journal:  EBioMedicine       Date:  2017-01-24       Impact factor: 8.143

5.  [The function and clinical value of Von Willebrand factor propeptide].

Authors:  Jie Yin; Changgeng Ruan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.